OnabotulinumtoxinA Intradetrusorial Injections Improve Sexual Function in Female Patients Affected by Multiple Sclerosis: Preliminary Results

Overview

Journal World J Urol

Specialty Urology

Date 2015 May 14

PMID 25966660

Citations 5

Authors

Antonella Giannantoni

Silvia Proietti

Guido Giusti

Marilena Gubbiotti

Enrico Millefiorini

Elisabetta Costantini

Alfredo Berardelli

Antonella Conte

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the effects of onabotulinum toxin type A (Onabot/A) intravesical injections on urinary and sexual function in a group of patients affected by multiple sclerosis (MS).

Methods: We enrolled 31 MS female patients with symptoms of overactive bladder and detrusor overactivity. All patients underwent urodynamics and were administered 3-day voiding diary, Incontinence Quality of Life (I-QoL) questionnaire, Female Sexual Function Index (FSFI) questionnaire, Hamilton Anxiety Rating Scale (HAM-A) and Hamilton Depression Rating Scale (HAM-D) before and 3 months after Onabot/A intravesical injection.

Results: Onabot/A injection significantly improved urinary symptoms as shown by the 3-day voiding diary, I-QoL questionnaire and the urodynamic variables. In addition, it also significantly improved sexual functioning in continent patients and psychological status as demonstrated by the increase in FSFI, HAM-A and HAM-D scores.

Conclusions: The Onabot/A-induced positive effect on sexual dysfunction in our MS patients is likely due to an indirect effect exerted by the overall urological clinical improvement on sexual function at both the psychological and emotional levels. The positive effect exerted by Onabot/A on the anxiety and depression scale also suggests that urinary symptoms have a negative impact on the psychological status of the patients.

Citing Articles

Sexual Dysfunction in Patients with Overactive Bladder Syndrome Treated with Botulinum Toxin.

Sondka-Migdalska J, Blaszczynski P, Jablonowski Z J Clin Med. 2024; 13(19).

PMID: 39407929 PMC: 11477138. DOI: 10.3390/jcm13195869.

The most effective sexual function and dysfunction interventions in individuals with multiple sclerosis: A systematic review and meta-analysis.

Afshar B, Amini L, Hasani M, Jahanfar S, Nabavi S Int J Reprod Biomed. 2022; 20(4):241-254.

PMID: 35822180 PMC: 9260072. DOI: 10.18502/ijrm.v20i4.10897.

Impact of intravesical onabotulinumtoxinA (Botox) on sexual function in patients with overactive bladder syndrome: a systematic review and meta-analysis.

Shawer S, Khunda A, Waring G, Ballard P Int Urogynecol J. 2022; 33(2):235-243.

PMID: 35024885 DOI: 10.1007/s00192-021-05072-7.

The impact of Mirabegron on sexual function in women with idiopathic overactive bladder.

Gubbiotti M, Giannantoni A, Cantaluppi S, Coluccia A, Ghezzi F, Serati M BMC Urol. 2019; 19(1):7.

PMID: 30665388 PMC: 6341751. DOI: 10.1186/s12894-019-0438-8.

Autonomic Dysregulation in Multiple Sclerosis.

Pinter A, Cseh D, Sarkozi A, Illigens B, Siepmann T Int J Mol Sci. 2015; 16(8):16920-52.

PMID: 26213927 PMC: 4581177. DOI: 10.3390/ijms160816920.

References

Rovner E, Dmochowski R, Chapple C, Thompson C, Lam W, Haag-Molkenteller C . OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2013; 32(8):1109-15. DOI: 10.1002/nau.22376. View

Coyne K, Sexton C, Thompson C, Kopp Z, Milsom I, Kaplan S . The impact of OAB on sexual health in men and women: results from EpiLUTS. J Sex Med. 2011; 8(6):1603-15. DOI: 10.1111/j.1743-6109.2011.02250.x. View

McDonald W, Compston A, Edan G, Goodkin D, Hartung H, Lublin F . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50(1):121-7. DOI: 10.1002/ana.1032. View

Tepavcevic D, Kostic J, Basuroski I, Stojsavljevic N, Pekmezovic T, Drulovic J . The impact of sexual dysfunction on the quality of life measured by MSQoL-54 in patients with multiple sclerosis. Mult Scler. 2008; 14(8):1131-6. DOI: 10.1177/1352458508093619. View

Wehbe S, Kellogg S, Whitmore K . Urogenital complaints and female sexual dysfunction. Part 2. J Sex Med. 2010; 7(7):2304-17. DOI: 10.1111/j.1743-6109.2010.01951.x. View

Hamilton M . The assessment of anxiety states by rating. Br J Med Psychol. 1959; 32(1):50-5. DOI: 10.1111/j.2044-8341.1959.tb00467.x. View

Kessler T, Fowler C, Panicker J . Sexual dysfunction in multiple sclerosis. Expert Rev Neurother. 2009; 9(3):341-50. DOI: 10.1586/14737175.9.3.341. View

Madhuvrata P, Singh M, Hasafa Z, Abdel-Fattah M . Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol. 2012; 62(5):816-30. DOI: 10.1016/j.eururo.2012.02.036. View

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

10.

Sand P, Goldberg R, Dmochowski R, McIlwain M, Dahl N . The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol. 2006; 195(6):1730-5. DOI: 10.1016/j.ajog.2006.08.013. View

11.

Dasgupta R, Fowler C . Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. Drugs. 2003; 63(2):153-66. DOI: 10.2165/00003495-200363020-00003. View

12.

Rogers R . Sexual function in women with pelvic floor disorders. Can Urol Assoc J. 2014; 7(9-10 Suppl 4):S199-201. PMC: 3919185. DOI: 10.5489/cuaj.1625. View

13.

Salonia A, Zanni G, Nappi R, Briganti A, Deho F, Fabbri F . Sexual dysfunction is common in women with lower urinary tract symptoms and urinary incontinence: results of a cross-sectional study. Eur Urol. 2004; 45(5):642-8. DOI: 10.1016/j.eururo.2003.11.023. View

14.

Proietti S, Giannantoni A, Sahai A, Khan M, Dasgupta P . Overactive bladder and sexual function: a nightmare couple. BJU Int. 2012; 110(7):921-4. DOI: 10.1111/j.1464-410X.2012.11411.x. View

15.

Mangera A, Apostolidis A, Andersson K, Dasgupta P, Giannantoni A, Roehrborn C . An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol. 2013; 65(5):981-90. DOI: 10.1016/j.eururo.2013.10.033. View

16.

Hajebrahimi S, Azaripour A, Sadeghi-Bazargani H . Tolterodine immediate release improves sexual function in women with overactive bladder. J Sex Med. 2008; 5(12):2880-5. DOI: 10.1111/j.1743-6109.2008.00976.x. View

17.

Kurtzke J . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33(11):1444-52. DOI: 10.1212/wnl.33.11.1444. View

18.

Yih J, Killinger K, Boura J, Peters K . Changes in sexual functioning in women after neuromodulation for voiding dysfunction. J Sex Med. 2013; 10(10):2477-83. DOI: 10.1111/jsm.12085. View

19.

Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R . The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000; 26(2):191-208. DOI: 10.1080/009262300278597. View

20.

Hamilton M . A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56-62. PMC: 495331. DOI: 10.1136/jnnp.23.1.56. View